HBB and Beta-thalassemia: The specimens with known mutations, as manifested by DNA sequencing of beta-thalassemia patients and their parents, were used than for initial evaluation of HRM approach for heterozygous mutations screening, which targeted 10 mutations namely, c.27_28insG, c.46delT, c.47G > A, c.79G > A, c.92G > C, c.92 + 5G > C, c.92 + 130G > C, c.126delC, c.126_129delCTTT and c.135delC of the beta-globin gene.